glp-1 medications market comparison Receptor Agonist Market: Exploring Opportunities The United States GLP-1 Agonists

They can improve weight loss and health and reduce mortality

BPAs potential health risks: pregnancy, fertility, obesity, and diabetes, and the socioeconomic confounders in the data [1:08:30]

However, the USDA reiterated that there is no overarching regulatory standard for the term "GLP-1 Friendly." Other companies, such as French yogurt maker Lactalis with its Ratio Pro Fiber yogurt, and restaurant chains Chipotle and Shake Shack with new protein-heavy menu items, are targeting GLP-1 users without explicitly mentioning the drugs on their packaging or menus

By July 31, 2025, the FDA had received 605 reports of adverse events linked to compounded semaglutide and 545 reports for compounded tirzepatide

Compounded Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan), while Oral Semaglutide is $289/mo month-to-month, or from $249/mo on the 6-month plan

Integrative Peptides' best-selling product, BPC-157, contains 500mcg of the systemically active, multi-functioning peptide